Hepatopulmonary Shunt Reduction With 177Lu-DOTATATE Therapy.
A 72-year-old man was diagnosed with well-differentiated neuroendocrine tumor of unknown primary with liver metastasis. All liver lesions were detectable only on Ga-DOTATATE PET/CT and were negative on F-FDG PET/CT. Intrahepatic Y radioembolization therapy was planned, but the hepatopulmonary shunt fraction was found to be 31.6%. Because the hepatopulmonary shunt fraction greater than 20% is an absolute contraindication to radioembolization, we decided to give him Lu-DOTATATE therapy. He received 4 courses of Lu-DOTATATE and showed regression in posttherapy Ga-DOTATATE PET/CT imaging. The hepatopulmonary shunt fraction was reduced to 8% after Lu-DOTATATE therapy.
From the Dokuz Eylül University, School of Medicine, Department of Nuclear Medicine, Izmir, Turkey.
Emine
E
Acar
Gamze
G
Çapa Kaya
Hatice
H
Durak
D000368:Aged; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008113:Liver Neoplasms / Q000532:radiotherapy* / Q000556:secondary; D008297:Male; D018358:Neuroendocrine Tumors / Q000473:pathology / Q000532:radiotherapy*; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use*; D000072078:Positron Emission Tomography Computed Tomography; D019275:Radiopharmaceuticals / Q000627:therapeutic use*
D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; C513399:gallium Ga 68 dotatate; C447941:lutetium Lu 177 dotatate; D015282:Octreotide